INFAI is specialized in the transfer of advanced analytical technology in the field of medical diagnostics and the development of innovative pharmaceutical products. The company is a pioneer in the use of stable isotopes in gastroenterology, cardiovascular and inborn metabolic diseases. Helicobacter Test INFAI (HTI) is approved in centralized procedure by EMA first time in all European countries since 1997 and available for routine diagnosis of Helicobacter pylori infection. Until now more than 7.8 Mio HTI performed worldwide. In the meantime, HTI is registered as medicinal product (medical prescription) in more than 40 countries worldwide.

​

INFAI's laboratories in Bochum, Germany and in York, England are equipped with state-of-the-art IRMS mass spectrometer and 600 MHz NMR spectrometer which is used to investigate metabolic disorders, cardiovascular diseases and a number of other diseases. These facilities are used for internal research and product development, but are also available for collaborative and contract research. In last 10 years, a range of non-invasive, highly efficient breath tests using stable isotopes has been developed. REFEX (for patients taking PPI’s or patients with atrophic gastritis), Gastromotal (13C octanoic acid gastric emptying test) and Pancreo-Lip (13C mixed triglyceride exocrine pancreatic function test) are in preparation for approval by EMA but now available for clinical studies. INFAI is associated with a number of companies in several European countries and outside the Europe. All other developed products of INFAI you can find on our website: www.infai1.com.

Since 1997, INFAI GmbH has been supporting the European Helicobacter & Microbiota Study Group (EHMSG) as Gold Sponsor.